Farallon Capital Management LLC Invests $13.91 Million in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Farallon Capital Management LLC purchased a new stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) in the 4th quarter, HoldingsChannel reports. The fund purchased 1,000,981 shares of the company’s stock, valued at approximately $13,914,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of TYRA. RA Capital Management L.P. grew its stake in shares of Tyra Biosciences by 2.1% in the fourth quarter. RA Capital Management L.P. now owns 10,637,290 shares of the company’s stock valued at $147,858,000 after buying an additional 220,681 shares in the last quarter. Alta Partners Management Company L.P. purchased a new position in Tyra Biosciences in the 4th quarter worth approximately $56,716,000. Boxer Capital Management LLC acquired a new stake in Tyra Biosciences in the fourth quarter valued at approximately $28,185,000. JPMorgan Chase & Co. raised its stake in shares of Tyra Biosciences by 1.1% during the third quarter. JPMorgan Chase & Co. now owns 368,647 shares of the company’s stock valued at $8,667,000 after purchasing an additional 3,896 shares during the period. Finally, Pictet Asset Management Holding SA acquired a new position in shares of Tyra Biosciences during the fourth quarter worth $4,921,000. Institutional investors and hedge funds own 84.14% of the company’s stock.

Analyst Ratings Changes

TYRA has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Tyra Biosciences in a research note on Monday, March 31st. Wedbush restated an “outperform” rating and set a $30.00 price objective on shares of Tyra Biosciences in a research note on Friday, March 28th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $30.83.

Tyra Biosciences Stock Up 10.3 %

Shares of NASDAQ TYRA opened at $10.07 on Friday. Tyra Biosciences, Inc. has a 52-week low of $6.42 and a 52-week high of $29.60. The stock has a market capitalization of $534.62 million, a P/E ratio of -6.25 and a beta of 1.17. The firm’s 50-day moving average price is $9.66 and its two-hundred day moving average price is $13.43.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.02. As a group, equities research analysts expect that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.